‘Real-world’ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase
Open Access
- 18 May 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 19 (5), 722-733
- https://doi.org/10.1093/europace/euw112
Abstract
Atrial fibrillation (AF) is commonly associated with a high risk of stroke, thromboembolism, and mortality. The 1-year follow-up of the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) Pilot Registry demonstrated a high mortality but good outcomes with European Society of Cardiology guideline-adherent therapy. Whether these ‘real-world’ observations on patients managed by European cardiologists extend to 2 years remains uncertain. In this report from the EORP-AF General Registry Pilot Phase, we provide data on the 2-year follow-up outcomes. Consistent with the 1-year follow-up report, only a small proportion of patients were symptomatic (24.9%), with minor differences between the different AF subtypes. Persistence of oral anticoagulant (OAC) therapy remains high at 2-years, with ∼80% of patients treated with OAC. The prescribing rates of non-vitamin K antagonist oral anticoagulants are progressively increasing (13.7% at 2 years). Rate and rhythm control approaches remained consistent across the entire follow-up observation. Overall mortality rates remained high, with 5.0% of patients dead during the 2-year follow-up, mostly due to cardiovascular causes (61.8%). Atrial fibrillation readmissions were frequent, particularly related to arrhythmias and heart failure. On multivariate analyses, any cardiovascular reason for admission rather than AF was significantly associated with increased mortality during the 2-year follow-up. In this 2-year follow-up report from EORP-AF, mortality rates with AF remain high from cardiovascular causes, despite the high prevalent use of OAC. Improved management strategies to reduce major adverse outcomes in AF patients are needed.Keywords
Funding Information
- Abbott Vascular Int.
- Amgen
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Boston Scientific
- The Bristol Myers Squibb and Pfizer Alliance
- The Alliance Daiichi Sankyo Europe GmbH
- Eli Lilly and Company
- Gedeon Richter Plc.
- Menarini Int. Op.
- MSD-Merck & Co.
- Novartis Pharma AG
- ResMed
- Sanofi
- Servier
This publication has 25 references indexed in Scilit:
- Asymptomatic Atrial FibrillationJAMA, 2015
- Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot RegistryEP Europace, 2015
- Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase IIAmerican Journal Of Medicine, 2015
- Stroke Prevention in Atrial FibrillationJama-Journal Of The American Medical Association, 2015
- Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomesInternational Journal of Cardiology, 2015
- Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novelThrombosis and Haemostasis, 2014
- Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)European Heart Journal, 2014
- A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General RegistryEP Europace, 2013
- Screening to identify unknown atrial fibrillationThrombosis and Haemostasis, 2013
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEP Europace, 2012